Overview

A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants

Status:
Completed
Trial end date:
2019-01-28
Target enrollment:
Participant gender:
Summary
This study will assess the safety and tolerability of RO7049389 compared to placebo in single- and multiple-ascending doses in healthy Chinese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche